Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease

Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease - Wang et al. 2019

Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease

Citation

HL Wang, CS Lu, TH Yeh, YM Shen, YH Weng, YZ Huang, RS Chang, YL Chen, YJ Chen, YW Lin, CC Hsu, HL Lin, CH Chiu and CC Chiu, "Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease", J Clin Neurol. 2019 Oct;15(4):488-495.

© 2019 Wang, Lu, Yeh, Shen, Weng, Huang, Chang, Chen, Chen, Lin, Hsu, Lin, Chiu and Chiu

Journal of Clinical Neurology | Volume 15, Issue 4, Pages 488-495

Previous
Previous

Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology

Next
Next

Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study